EP2097139A1 - 2-{[2-(substituierte amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidate - Google Patents

2-{[2-(substituierte amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidate

Info

Publication number
EP2097139A1
EP2097139A1 EP06844637A EP06844637A EP2097139A1 EP 2097139 A1 EP2097139 A1 EP 2097139A1 EP 06844637 A EP06844637 A EP 06844637A EP 06844637 A EP06844637 A EP 06844637A EP 2097139 A1 EP2097139 A1 EP 2097139A1
Authority
EP
European Patent Office
Prior art keywords
ethyl
compound
chloroethyl
tetrakis
phosphorodiamidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06844637A
Other languages
English (en)
French (fr)
Inventor
Wenli Ma
Kevin T. Weber
Robert M. Yee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of EP2097139A1 publication Critical patent/EP2097139A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Definitions

  • This invention relates to 2- ⁇ [2-(substituted amino)ethyl]sulfonyl ⁇ ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation and intermediates in their preparation.
  • L is an electron withdrawing leaving group
  • the compounds are stated to be useful drugs for the selective treatment of target tissues which contain compatible glutathione iS'-transferase (GST) isoenzymes, and simultaneously elevate the levels of granulocyte macrophage progenitor cells in bone marrow.
  • GST glutathione iS'-transferase
  • Disclosed embodiments for L include those that generate a drug that is cytotoxic to unwanted cells, including the phosphoramidate and phosphorodiamidate mustards.
  • TER 286 It is referred to in the patent as TER 286 and named as 7-glutamyl-a ⁇ -amino-
  • This compound later referred to as TLK286, has the uninverted CAS name L- ⁇ -glutamyl- 3 - [ [2- [[bis [bis(2-chloroethyl)amino]phosphinyl] oxy] ethyl] sulfonyl]-L-alanyl-2-phenyl- (2R)-glycine.
  • the neutral compound its recommended International Nonproprietary Name is canfosfamide; and as its hydrochloride acid addition salt, its United States
  • Canfosfamide hydrochloride Adopted Name is canfosfamide hydrochloride.
  • Canfosfamide and its salts are anticancer compounds that are activated by the actions of GST Pl-I, and by GST Al-I, to release the cytotoxic phosphorodiamidate mustard moiety.
  • canfosfamide has been shown to be more potent in the M6709 human colon carcinoma cell line selected for resistance to doxorubicin and the MCF-7 human breast carcinoma cell line selected for resistance to cyclophosphamide, both of which overexpress GST Pl-I, over their parental cell lines; and in murine xenografts of M7609 engineered to have high, medium, and low levels of GST Pl-I, the potency of canfosfamide hydrochloride was positively correlated with the level of GST Pl-I (Morgan et al., "Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione ⁇ -transferase", Cancer Res., 58, 2568-2575 (1998)).
  • Canfosfamide hydrochloride is currently being evaluated in multiple clinical trials for the treatment of ovarian, breast, non-small cell lung, and colorectal cancers. It has demonstrated significant single agent antitumor activity and improvement in survival in patients with non-small cell lung cancer and ovarian cancer, and single agent antitumor activity in colorectal and breast cancer.
  • Evidence from in vitro cell culture and tumor biopsies indicates that canfosfamide is non-cross-resistant to platinum, paclitaxel, and doxorubicin (Rosario et al., "Cellular response to a glutathione ⁇ -transferase Pl-I activated prodrug", MoI. Pharmacol, 58, 167-174 (2000)), and also to gemcitabine. Patients treated with canfosfamide hydrochloride show a very low incidence of clinically significant hematological toxicity.
  • L is an electron withdrawing leaving group
  • S + is S or Se
  • Y is selected from the group consisting of
  • X is a halogen atom
  • Q is O, S, or NH
  • R is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted heteroaryl, or is R 1 CO-, R 1 NHCO-, R 1 SO 2 -, or R 1 NHSO 2 - where R 1 is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted heteroaryl; or R-Q together is chlorine; and their salts, as antitumor agents.
  • PCT Publication No. WO 2005/118601 discloses compounds of the formulae
  • each R is independently hydrogen, Ci -6 alkyl, or -CH 2 CH 2 X, where each X is independently Cl, Br, C 1-6 alkanesulfonyloxy, halo-d- 6 alkanesulfonyloxy, or benzenesulfonyloxy optionally substituted with up to three substituents selected from halo, Ci -3 alkyl, halo-Ci -3 alkyl, C 1-3 alkyloxy, or halo-Ci -3 alkyloxy, provided that at least two R's in each phosphorodiamidate group are -CH 2 CH 2 X;
  • R 1 is optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;
  • R 2 is optionally substituted alkanediyl, optionally substituted heteroalkanediyl, optionally substituted arenediyl, optionally substituted arenedialkyl, optionally substituted heteroarenediyl, or optionally substituted heteroarenedialkyl, and their salts, as antitumor agents.
  • the compounds are said to spontaneously liberate phosphoramide mustards via beta- elimination, and to be more potent than the corresponding phosphoramide mustards against V-79 Chinese hamster lung fibroblasts in vitro. Some of the compounds were said to show excellent in vivo antitumor activity in CD2F1 mice against the P388/0 (wild) and P388/CPA (cyclophosphamide-resistant) leukemia cell lines.
  • this invention is compounds of formula A:
  • each R is independently methyl, ethyl, propyl, or isopropyl, or -NR 2 together is 1 -pyrrolidinyl or 1-piperidinyl.
  • this invention is pharmaceutical compositions comprising a compound of the first aspect of this invention.
  • this invention is methods of treating cancer by the administration of a compound of the first aspect of this invention or a pharmaceutical composition of the second aspect of this invention; alone or in combination with other anticancer therapies.
  • this invention is methods of preparing compounds of the first aspect of this invention, and intermediates in the methods.
  • a “therapeutically effective amount” means that amount which, when administered to a human for treating a cancer, is sufficient to effect treatment for the cancer.
  • “Treating” or “treatment” of a cancer in a human includes one or more of:
  • Combination therapy means the administration of a compound of the first aspects of this invention and another anticancer therapy during the course of cancer chemotherapy. Such combination therapy may involve the administration of the compound of the first aspect of this invention before, during, and/or after the administration of the another anticancer therapy.
  • the administration of the compound of the first aspect of this invention may be separated in time from the administration of the another anticancer therapy by up to several weeks, and may precede it or follow it, but more commonly the administration of the compound of the first aspect of this invention will accompany at least one aspect of the another anticancer therapy (such as the administration of one dose of a chemotherapeutic agent, molecular targeted therapy agent, biologic therapy agent, or radiation therapy) within up to 48 hours, and most commonly within less than 24 hours.
  • a chemotherapeutic agent such as the administration of one dose of a chemotherapeutic agent, molecular targeted therapy agent, biologic therapy agent, or radiation therapy
  • “Another anticancer therapy” is an anticancer therapy that is not a treatment with a compound of the first aspect of this invention.
  • Such “another anticancer therapies” include chemotherapy; molecular targeted therapy; biologic therapy; and radiotherapy. These therapies are those used as monotherapy or in combination therapy.
  • Chemotherapeutic agents include: alkylating agents, including: alkyl sulfonates such as busulfan, ethyleneimine derivatives such as thiotepa, nitrogen mustards such as chlorambucil, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, and uramustine, nitrosoureas such as carmustine, lomustine, and streptozocin, triazenes such as dacarbazine, procarbazine, and temozolamide, and platinum compounds such as cisplatin, carboplatin, oxaliplatin, satraplatin, and picoplatin; antimetabolites, including: antifolates such as methotrexate, permetrexed, raltitrexed, and trimetrexate, purine analogs such as cladribine, chlorodeoxyadenosine, clofarabine, fludara
  • Molecular targeted therapy agents include: functional therapeutic agents, including: gene therapy agents, antisense therapy agents, tyrosine kinase inhibitors such as erlotinib hydrochloride, gefitinib, imatinib mesylate, and semaxanib, and gene expression modulators such as the retinoids and rexinoids, e.g.
  • phenotype-directed therapy agents including: monoclonal antibodies such as alemtuzumab, bevacizumab, cetuximab, ibritumomab tiuxetan, rituximab, and trastuzumab, immunotoxins such as gemtuzumab ozogamicin, and radioimmunoconjugates such as 13I I-tositumomab; and cancer vaccines.
  • Biologic therapy agents include: interferons such as interferon-ofe a and interferon-c ⁇ b ? and interleukins such as aldesleukin, denileukin diftitox, and oprelvekin.
  • anticancer therapies include the use of protective or adjunctive agents, including: cytoprotective agents such as amifostine, dexrazoxane, and mesna, phosphonates such as pamidronate and zoledronic acid, and stimulating factors such as epoetin, darbeopetin, filgrastim, PEG-fllgrastim, and sargramostim.
  • cytoprotective agents such as amifostine, dexrazoxane, and mesna
  • phosphonates such as pamidronate and zoledronic acid
  • stimulating factors such as epoetin, darbeopetin, filgrastim, PEG-fllgrastim, and sargramostim.
  • Combination cancer therapy regimens with which the compounds of the first aspect of this invention may be combined include all regimens involving the use of two or more of the anticancer therapies (anticancer agents) such as those mentioned in paragraphs [0022] to [0024] above and/or radiotherapy, optionally including protective and adjunctive agents such as those mentioned in paragraph [0025] above; and the compound of the first aspect of this invention can be added to existing anticancer regimens known for the treatment of various cancers, such as the regimens mentioned in such books as Chabner and Longo, eds., "Cancer Chemotherapy and Biotherapy: Principles and Practice", 3rd ed.
  • combination chemotherapeutic regimens are known to the art, such as combinations of platinum compounds and taxanes, e.g. carboplatin/paclitaxel, capecitabine/docetaxel, the "Cooper regimen", fluorouracil-levamisole, fluorouracil- leucovorin, methotrexate-leucovorin, and those known by the acronyms ABDIC, ABVD, AC, ADIC, AI, BACOD, BACOP, BVCPP, CABO, CAD, CAE, CAF, CAP, CD, CEC, CF, CHOP, CHOP+rituximab, CIC, CMF, CMFP, CyADIC, CyVADIC, DAC, DVD, FAC, FAC-S, FAM-S, FOLFOX-4, FOLFOX-6, M-BACOD, MACOB-B, MAID, MOPP, MVAC, PCV, T-5, VAC, VAD, VAPA, VAP-Cy
  • Combinations of chemotherapies and molecular targeted therapies, biologic therapies, and radiation therapies are also well known to the art; including therapies such as trastuzumab + paclitaxel, alone or in further combination with carboplatin, for certain breast cancers, and many other such regimens for other cancers; and the “Dublin regimen” and “Michigan regimen”, both for esophageal cancer, and many other such regimens for other cancers.
  • compositions of this invention are words of inclusion and not of limitation and mean to specify the presence of stated components, groups, steps, and the like but not to exclude the presence or addition of other components, groups, steps, and the like. Thus “comprising” does not mean “consisting of, “consisting substantially of, or “consisting only of; and, for example, a pharmaceutical composition "comprising” a compound must contain that compound but may also may contain other active ingredients and/or excipients. [0030] Compounds of this invention
  • this invention is compounds of formula A:
  • each R is independently methyl, ethyl, propyl, or isopropyl, or -NR 2 together is pyrrolidin- 1 -yl or piperidin- 1 -yl.
  • Representative compounds of the invention are those where each R is independently methyl, ethyl, or isopropyl; and where each R is the same; and where -NR 2 is dimethylamino (compound IA), diethylamino (compound 2A), diisopropylamino (compound 3A), pyrrolidin- 1-yl (compound 4A), or piperidin- 1-yl (compound 5A), and their acid addition salts.
  • Acid addition salts for example, pharmaceutically acceptable acid addition salts of the compounds of formula A are included in the present invention and are useful in the compositions, methods, and uses described in this application.
  • Suitable salts are those formed when inorganic acids (e.g. hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, and chlorosulfonic acids) or organic acids (e.g. acetic, propionic, oxalic, malic, maleic, malonic, fumaric, citric, tartaric, lactic, succinic, and aceturic acids, and alkane- or arenesulfonic acids such as methanesulfonic, ethanesulfonic,
  • inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, and chlorosulfonic acids
  • organic acids e.g. acetic, propionic, oxalic, malic, maleic, malonic, fumaric
  • Such salts are preferably formed with pharmaceutically acceptable acids.
  • a 2-(NR 2 )-ethanethiol is converted into a 2- ⁇ [2-(NR 2 )ethyl]thio ⁇ ethyl N,N,N' ) N'-tetrakis(2-chloroethyl)phosphorodiamidate by reaction with a 2-X-ethyl N,N,N'N'-tetrakis(2-chloroethyl)phosphorodiamidate (where X is a leaving group such as Cl, Br, Cj -6 alkanesulfonyloxy, halo-Ci -6 alkanesulfonyloxy, or benzenesulfonyloxy optionally substituted with up to three substituents selected from halo, Cj -3 alkyl, halo-Ci -3 alkyl, Ci -3 alkyloxy, or halo-Ci -3 alkyloxy, such as methanesulfonyl
  • a typical procedure involves treating the 2-(NR 2 )-ethanethiol with a polar solvent such as water, an alkanol, dimethylformamide, or tetrahydrofuran, and a base such as a hydroxide, alkoxide, fluoride, or hydride, or a tertiary amine or amide base to form the thiolate anion, followed by adding the phosphorodiamidate.
  • Thiolate displacement of the leaving group X of the phosphorodiamidate gives the 2- ⁇ [2-(NR 2 )ethyl]thio ⁇ ethyl N, ⁇ /;N' / N'-tetrakis(2-chloroethyl)phosphorodiamidate.
  • 2-(Dimethylamino)ethanethiol and 2-(diethylamino)ethanethiol are both readily commercially available as the hydrochloride salts.
  • 2-(NR 2 )-ethanethiol When the 2-(NR 2 )-ethanethiol is not available, it may be prepared by a method such as reacting a 2-(NR 2 )-ethyl halide [the chloride is shown in the reaction scheme] with thiourea to prepare a 2-(NR 2 )-ethyl- isothiourea, which may be isolated as an acid addition salt if desired.
  • the 2-(NR 2 )-ethylisothiourea When the 2-(NR 2 )-ethylisothiourea is treated with base, the corresponding 2-(NR 2 )-ethanethiolate is formed in solution, and the resulting solution may be used directly in the formation of the 2- ⁇ [2-(NR 2 )ethyl]thio ⁇ ethyl 7V " ,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidate.
  • a typical procedure involves treating a 2-( ⁇ R 2 )-ethyl chloride hydrochloride with thiourea in a lower alkanol, such as ethanol, at elevated temperature.
  • the isothiourea precipitates as a dihydrochloride salt, which may be isolated by filtration.
  • the isothiourea is suspended in a lower alkanol and treated with base to form the thiolate anion, followed by adding the phosphorodiamidate.
  • Thiolate displacement of the leaving group X of the phosphorodiamidate gives the 2- ⁇ [2-(NR 2 )ethyl)thio]ethyl N,N,N' N'-tetrakis(2-chloroethyl)phosphorodiamidate.
  • the 2- ⁇ [2-(NR 2 )ethyl]thio ⁇ ethyl N,7V,N',N'-tetrakis(2-chloroethyl)phosphorodiamidate is oxidized to the corresponding 2- ⁇ [2-(NR 2 )ethyl] sulfonyl ⁇ ethyl N;N,N',N'-tetrakis(2-chloroethyl)phos ⁇ horodiamidate.
  • This oxidation may be performed by any of the methods known in the art for the oxidation of sulfides to sulfones, such as the use of peracids (peroxycarboxylic acids), persulfates, perborates, peroxides, ozone, iodosyl reagents, halogens, and the like.
  • a typical procedure involves dissolving the 2- ⁇ [2-( ⁇ R 2 )ethyl]thio ⁇ ethyl N, ⁇ iV',N'-tetrakis(2-chloroethyl)phosphorodiamidate in a solvent such as dichloromethane, acetic acid, or isopropyl acetate at reduced temperature, followed by the addition of the peracid (e.g. peracetic acid) in excess.
  • the oxidation is performed under conditions that minimize oxidation of the amine nitrogen, such as by performing the oxidation at a sufficiently low pH to stabilize the amine as an ammonium cation.
  • Oxidation e.g. with peroxyacid
  • the 2- ⁇ [2-(hydroxy)ethyl]thio ⁇ ethyl N,N,N'N'-tetrakis(2-chloroethyl)phosphorodiamidate is oxidized to 2- ⁇ [2-(hydroxy)ethyl]sulfonyl ⁇ ethyl N,N,N',N'-tetrakis(2-chloroethyl)- phosphorodiamidate.
  • This oxidation may be performed by any of the methods described for the second step of Method 1 in paragraph [0039]; however, in Method 2 there is no risk of amine oxidation.
  • the hydroxy group of the 2- ⁇ [2-(hydroxy)ethyl]sulfonyl ⁇ ethyl -V,N,N',N'-tetrakis(2-chloroethyl)- phosphorodiamidate is esterified by reaction with a sulfonic acid anhydride, preferably one that gives a strong leaving group, such as the anhydrides of trifluoromethanesulfonic, fluorosulfonic, or pentafluorobenzenesulfonic acids.
  • the 2- ⁇ [2-(hydroxy)ethyl]sulfonyl ⁇ ethyl JV,N,N',N'-tetrakis(2-chloroethyl)- phosphorodiamidate is dissolved in a non-nucleophilic, preferably low-boiling, solvent such as dichloromethane, and the anhydride added, for example at 0 0 C.
  • a non-nucleophilic, preferably low-boiling, solvent such as dichloromethane
  • anhydride for example at 0 0 C.
  • the sulfonate ester may be isolated if desired, but is more conveniently used directly in the next step.
  • the sulfonate ester is displaced with excess R 2 NH.
  • an excess of the amine is added to the solution from the third step and the reaction is allowed to proceed to completion.
  • the 2- ⁇ [2-(NR 2 )ethyl]thio ⁇ ethyl iV, ⁇ r ,iV'-V-tetrakis(2-chloroethyl)phosphorodiamidate is conveniently isolated by addition of aqueous acid to the reaction mixture, removal of the organic layer, neutralization with a weak base (such as solid NaHCO 3 ), re-extraction of the 2- ⁇ [2-(NR 2 )ethyl]thio ⁇ ethyl jV,N,iv " 'iV-tetrakis(2-chloroethyl)phosphorodiamidate into an organic solvent, and removal of that solvent.
  • the compounds of formula A may be converted to acid addition salts by reaction with the appropriate acids, using techniques well known to a person of ordinary skill in the art for the formation of acid addition salts.
  • the acid used, and the reaction conditions may be chosen to give acid addition salts that are pharmaceutically acceptable and that - have a form convenient for isolation and formulation, such as a solid form (for example, amorphous or crystalline).
  • Pharmaceutical compositions and administration may be chosen to give acid addition salts that are pharmaceutically acceptable and that - have a form convenient for isolation and formulation, such as a solid form (for example, amorphous or crystalline).
  • the second aspect of this invention is pharmaceutical compositions comprising a compound of the first aspect of this invention and optionally a pharmaceutically acceptable excipient.
  • the compounds of the first aspect of this invention may be administered by any route suitable to the subject being treated and the nature of the subject's condition. Routes of administration include administration by injection, including intravenous, intraperitoneal, intramuscular, and subcutaneous injection, by transmucosal or transdermal delivery, through topical applications, nasal spray, suppository and the like or may be administered orally.
  • Pharmaceutical compositions may optionally be liposomal compositions, emulsions, compositions designed to administer the drug across mucosal membranes or transdermal compositions.
  • compositions for each of these methods of administration may be found, for example, in Gennaro, ed., "Remington: The Science and Practice of Pharmacy", 20th ed. (2000), Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, U.S.A.
  • Typical compositions will be either oral or solutions for intravenous infusion.
  • Typical dosage forms will be tablets (including coated tablets and “caplets”) or capsules (including hard gelatin capsules and "softgels”) for oral administration, solutions for intravenous infusion, and solids (especially lyophilized powders) for reconstitution as solutions for intravenous infusion.
  • the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, preferably in unit dosage form suitable for single administration of a precise dosage.
  • the compositions may contain suitable pharmaceutically-acceptable excipients, including adjuvants which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • “Pharmaceutically acceptable excipient” refers to an excipient or mixture of excipients which does not interfere with the effectiveness of the biological activity of the active ingredient(s) and which is not toxic to the host to which it is administered.
  • conventional excipients include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • Liquid pharmacologically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., an active compound as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary excipients such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • auxiliary excipients such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • the composition will generally take the form of a tablet or capsule, or it may be an aqueous or nonaqueous solution, suspension or syrup. Tablets and capsules are preferred oral administration forms. Tablets and capsules for oral use will generally include one or more commonly used excipients such as lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. When liquid suspensions are used, the active agent may be combined with emulsifying and suspending excipients. If desired, flavoring, coloring and/or sweetening agents may be added as well. Other optional excipients for incorporation into an oral composition include preservatives, suspending agents, thickening agents, and the like.
  • Injectable pharmaceutical compositions can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solubilization or suspension in liquid prior to injection, or as emulsions or liposomal compositions.
  • the sterile injectable composition may also be a sterile injectable solution or a suspension in a nontoxic parenterally acceptable diluent or solvent.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils, fatty esters or polyols are conventionally employed as solvents or suspending media.
  • compositions of this invention may also be formulated as lyophilized powders for parenteral administration. Powders may be reconstituted by addition of water or other primarily aqueous medium and then further diluted with a suitable diluent prior to use.
  • the liquid composition is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are isotonic saline solution, aqueous 5% dextrose solution, and buffered sodium or ammonium acetate solution.
  • Pharmaceutically acceptable solid or liquid excipients may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • a pharmaceutical composition of the present invention is packaged in a container with a label, or instructions, or both, indicating use of the pharmaceutical composition in the treatment of cancer.
  • the pharmaceutical composition may additionally contain one or more other pharmacologically active agents in addition to a compound of this invention. These additional active agents will typically be useful in treating cancer, or for enhancing the treatment of cancer by compounds of this invention. [0056] Methods of using the compounds
  • the compounds of the first aspect of this invention have activity against human cancer cell lines, as demonstrated in the in vitro and in vivo Examples below, and are therefore considered to be useful as human cancer chemotherapeutic agents, for the treatment of human cancers.
  • the third aspect of this invention includes methods of treating cancer in humans by administering a therapeutically effective amount of a compound of the first aspect of this invention, or a pharmaceutical composition of the second aspect of this invention, to the human; and the use of the compounds of the first aspect of this invention in the manufacture of medicaments for the treatment of cancer in humans.
  • the methods further comprise treating the human with another anticancer therapy, such as a therapy already conventional for the cancer being treated.
  • Cancers that are particularly treatable by the method of this invention are cancers with sensitivity to inducers of apoptosis, and more specifically those cancers that express or, particularly, overexpress one or more glutathione S-transferase isoenzymes. Cancers that express or overexpress one or more glutathione S-transferase isoenzymes when treated with other anticancer compounds or combination cancer chemotherapy regimens are especially treatable by the method of this invention.
  • Such cancers include cancers of the brain, breast, bladder, cervix, colon and rectum, esophagus, head and neck, kidney, lung, liver, ovary, pancreas, prostate, and stomach; leukemias such as ALL, AML, AMML, CLL, CML, CMML, and hairy cell leukemia; Hodgkin's and non-Hodgkin's lymphomas; mesotheliomas, multiple myeloma; and sarcomas of bone and soft tissue.
  • Cancers particularly treatable by the method of this invention include breast, ovarian, colorectal, and non-small cell lung cancers.
  • the amount of the compound of the first aspect of this invention that is administered to the human should be a therapeutically effective amount when used alone or when used in conjunction with the another anticancer therapy (if the compound of the first aspect of this invention is administered in conjunction with another anticancer therapy); and similarly the amount of the another anticancer therapy that is administered to the mammal (if the compound of the first aspect of this invention is administered in conjunction with another anticancer therapy) should be a therapeutically effective amount when used in conjunction with the compound of the first aspect of this invention.
  • the therapeutically effective amount of either the compound of the first aspect of this invention and the amount of the another anticancer therapy when administered in combination cancer chemotherapy may each be less than the amount which would be therapeutically effective if delivered to the human alone. It is common in cancer therapy, though, to use the maximum tolerated dose of the or each therapy, with a reduction only because of common toxicity of the therapies used or potentiation of the toxicity of one therapy by another.
  • compounds of the first aspect of this invention will be administrable at essentially their maximum tolerated dose as a single agent, and no reduction in the amount of the another anticancer therapy will be required.
  • the compounds of the first aspect of this invention, or pharmaceutical compositions of the second aspect of this invention are thus used to treat cancer in humans requiring such treatment, by administering a therapeutically effective amount of the chosen compound or composition.
  • Therapeutically effective amounts of compounds of the invention are in the range of 10 - 10,000 mg/m 2 , for example, 30 - 3000 mg/m 2 or 100 - 1000 mg/m 2 . Dosing maybe at 1 - 35 day intervals; for example, about
  • Suitable dosing for the other anticancer therapy will be the dosing already established for that therapy, as described in such documents as those listed in paragraph [0026].
  • Such dosing varies widely with the therapy: for example, capecitabine (2500 mg/m 2 orally) is dosed twice daily for 2 weeks on and 1 week off, imatinib mesylate (400 or 600 mg/day orally) is dosed daily, rituximab is dosed weekly, paclitaxel (135 - 175 mg/m 2 ) and docetaxel (60 - 100 mg/m 2 ) are dosed weekly to every three weeks, carboplatin (4 - 6 mg/mL » min) is dosed once every 3 or 4 weeks (though the doses may be split and administered over several days), nitrosourea alkylating agents such as carmustine are dosed as infrequently as once every 6 weeks. Radiotherapy may be administered as frequently as weekly (or
  • a person of ordinary skill in the art of cancer therapy will be able to ascertain a therapeutically effective amount of the compound of the first or second aspect of this invention and a therapeutically effective amount of another anticancer therapy for a given cancer and stage of disease without undue experimentation and in reliance upon personal knowledge and the disclosure of this application.
  • Combination therapies include the combination administration of a compound of the first aspect of this invention with a platinum compound such as carboplatin or cisplatin, optionally in further combination with gemcitabine or a taxane such as docetaxel or paclitaxel; with gemcitabine; with a taxane; with an anthracycline such as doxorubicin or liposomal doxorubicin; with oxaliplatin, optionally in further combination with capecitabine or fluorouracil/leucovorin; and with gemcitabine or a platinum compound such as carboplatin or cisplatin, in further combination with a vinca alkaloid such as vinorelbine.
  • a platinum compound such as carboplatin or cisplatin, optionally in further combination with gemcitabine or a taxane such as docetaxel or paclitaxel
  • gemcitabine with a taxane
  • an anthracycline such as doxorubicin or lipo
  • the compounds of this invention are prepared by conventional methods of organic chemistry. See, for example, Larock, "Comprehensive Organic Transformations", (1989), Wiley- VCH, New York, New York, U.S.A.
  • the compounds of this invention can be synthesized, generally following the synthetic schemes illustrated earlier in this application, as shown in the following examples or by modifying the exemplified synthesis by means known to those of ordinary skill in the art.
  • the mixture was acidified to pH 7 with 1.0 M aqueous H 3 PO 4 and concentrated under vacuum to a thick slurry.
  • the slurry was taken up in ethyl acetate (800 mL) and washed with 5% aqueous NaHCO 3 (2 x 800 mL).
  • the organic layer was separated, dried over anhydrous MgSO 4 , filtered, and concentrated under vacuum to give 2- ⁇ [2-(diisopropylamino)ethyl]thio ⁇ ethyl N,N,JV',N'-tetrakis(2-chloroethyl)- phosphorodiamidate as a clear oil (2.3 g, 86% yield).
  • reaction mixture was diluted with ethyl acetate (800 mL) and washed with a 1 :1 mixture of 0.2M aqueous Na 2 S 2 O 4 and saturated aqueous NaHCO 3 (2 x 800 mL).
  • the organic layer was separated, dried over anhydrous MgSO 4 , filtered, and treated with excess hydrochloric acid (4.0M in dioxane).
  • the mixture was stirred at room temperature until all the 2-(4-bromobenzenesulfonyloxy)ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidate was consumed, as determined by HPLC-ELSD.
  • the mixture was acidified to pH 7 with 1.0 M aqueous H 3 PO 4 and concentrated under vacuum to a thick slurry.
  • the slurry was taken up in ethyl acetate (400 mL) and washed with 5% aqueous NaHCO 3 (2 x 400 mL) and then with aqueous HCl (2 x 400 mL).
  • the Oxone ® was added in approximately 250 mL portions over 3 hours with conversion of the 2- ⁇ [2-(diethylamino)ethyl]thio ⁇ - ethyl N, N,N'N'-tetrakis(2-chloroethyl)phosphorodiamidate to
  • N,-y7V'iV'-tetrakis(2-chloroethyl)phosphorodiamidate (8.35 mL of 0.82M solution in toluene, 6.84 mmol) was added, and the reaction mixture allowed to warm to room temperature. After 12 hours, the mixture was filtered, neutralized to pH 7 with IM aqueous H 3 PO 4 , and concentrated under vacuum to a thick syrup. This syrup was diluted with isopropyl acetate (200 mL), and washed with water (3 x 200 mL). The isopropyl acetate layer was dried over MgSO 4 , filtered, and concentrated under vacuum to give a clear oil.
  • This oil was purified on a 30 mm x 150 mm silica gel column using a gradient of 70:30 ethyl acetate/hexanes to 100% ethyl acetate to give 2- ⁇ [2-(hydroxy)ethyl]thio ⁇ - ethyl N,iV,iV',N'-tetrak:is(2-chloroethyl)phosphorodiamidate as a clear oil (1.41 g, 55% yield).
  • the reaction mixture was allowed to warm to room temperature and kept for 3 hours.
  • the reaction mixture was diluted with isopropyl acetate (200 mL) and washed with 0.1 M aqueous Na 2 S 2 O 3 (2 x 200 mL) and water (200 mL).
  • the isopropyl acetate layer was dried over MgSO 4 , filtered, and concentrated under vacuum to give 2- ⁇ [2-(hydroxy)ethyl]sulfonyl ⁇ ethyl N,N, JV',N'-tetrakis(2-chloroethyl)- phosphorodiamidate as a clear oil (3.89 g, 81% yield).
  • the reaction mixture was added to a solution of diethyl amine (64 ⁇ L, 0.62 mmol) in isopropyl acetate (2 mL), and this was allowed to stand for 30 minutes.
  • the reaction mixture was diluted with isopropyl acetate (10 mL) and washed with 5% aqueous NaHCO 3 (2 x 10 mL) and IM aqueous HCl (2 x 5 mL).
  • the aqueous acidic fractions were combined, washed with dichloromethane (10 mL), and solid NaHCO 3 was added to pH>9.
  • the citrate salt of compound IA was prepared as a solid by treating compound IA with citric acid using methods similar to those used to prepare the citrate salt of compound 2A, while the hydrochloride salt (Synthetic Example 5) was prepared as an oil.
  • the fumarate, tartrate, and p-toluenesulfonate salts of compound 2 A were prepared as solids, and the maleate, methanesulfonate, phosphate, succinate, and sulfate salts prepared as oils, by reacting compound 2A with the corresponding acids using methods similar to those used to prepare the citrate salt, while the hydrochloride salt (Synthetic Example 4) was prepared as an oil.
  • the citrate, fumarate, hydrochloride, maleate, methanesulfonate, phosphate, succinate, and sulfate salts of compound 3A were prepared as oils by similar methods, as was the hydrochloride salt (Synthetic Example 1).
  • the citrate and tartrate salts of compound 5A were prepared as solids, and the maleate, succinate, and p-toluenesulfonate salts as oils, by similar methods, and the hydrochloride salt (Synthetic Example 3) was prepared as a solid.
  • Other salts of compounds of formula A may similarly be prepared by using the appropriate acids, preferably in solvents that permit the isolation of the acid addition salts as solids.
  • the hydrochloride salt of compound 2 A had a solubility in water of at least 50 mg/mL, the citrate salt had a solubility of about 19 mg/mL, and the tartrate salt was slightly more soluble than the citrate salt.
  • the hydrochloride salt of compound IA was also highly soluble in water, while the citrate salt was somewhat more soluble than the citrate salt of compound 2A.
  • In vitro Example 1 Cytotoxicity/growth inhibition assay.
  • the human cancer cell lines DLD-I colonal adenocarcinoma
  • LNCaP prostate carcinoma
  • MIA PaCa-2 pancreatic carcinoma
  • DLD-I colonal adenocarcinoma
  • LNCaP prostate carcinoma
  • MIA PaCa-2 pancreatic carcinoma
  • the CellTiter-Glo assay kit was obtained from Promega Corporation, Madison, Wisconsin, U.S.A. All products were used in accordance with manufacturer's directions. All assays were conducted in triplicate wells, with dimethyl sulfoxide (DMSO) solvent control.
  • DMSO dimethyl sulfoxide
  • Log-phase cells were trypsinized, collected by centrifugation, and resuspended in a small volume of fresh medium, and the density of viable cells was determined following Trypan Blue staining.
  • Cells were diluted in fresh media (3 x 10 3 cells/mL for DLD- 1 , MIA PaCa-2, and MX- 1 , and 6 x 10 3 cells/mL for LNCaP), and added at 150 ⁇ L/well to 96-well plates, and incubated for several hours to allow attachment in the case of adherent cells.
  • Example 1 MX-I xenograft assay, intraperitoneal administration.
  • mice Female athymic nu/nu mice (Harlan, Indianapolis, Indiana, U.S.A. or similar vendor), 6-8 weeks old (approximately 20 g), were implanted in the mammary fat pad of the right fore flank with 20-30 mg pieces of MX-I tumor harvested from similar nu/nu mice that had previously been implanted with the MX-I tumor. Approximately 7-10 days after tumor transplantation, when the tumor weight was approximately 50-200 mg, the mice were assigned to treatment groups such that each treatment group had a similar average tumor weight at the start of treatment.
  • mice were treated with compounds 2 A and 3A at 50 mg/Kg and compounds IA, 2A, 3 A, and 5A at 100 mg/Kg, in all cases as the hydrochloride salts dissolved in aqueous 5% dextrose, by intraperitoneal injection once/day for 5 consecutive days, with vehicle control. Tumor mass, estimated from volume, was measured twice weekly; and tumor growth inhibition was measured when the average tumor mass in the control group first exceeded 2000 mg. All compounds were active in this assay, with tumor growth inhibition compared to vehicle of 70% and 23% for compounds 2 A and 3 A, respectively, at 50 mg/Kg, and 100%, 100%, 100%, and 91% for compounds IA, 2 A, 3 A, and 5A, respectively, at 100 mg/Kg. [0098] In vivo Example 2: MX-I xenograft assay, oral administration.
  • Example 1 A study similar to that described in In vivo Example 1 was performed using oral administration of compounds 2 A and 3 A. Groups of mice were treated with compound 2A at 100, 150, 200, or 300 mg/Kg, or compound 3A at 150 mg/Kg, in each case as the • hydrochloride salts dissolved in water, by gavage once/day for 5 consecutive days, with vehicle control. Both compounds were active in this assay and compound 2A caused dose-dependent tumor inhibition. Compound 2A caused a dose-dependent inhibition of tumor growth between 92% (100 mg/Kg) and 100% (300 mg/Kg) compared to vehicle, and compound 3A caused an inhibition of 98% (150 mg/Kg).
  • Example 3 MX-I xenograft assay, intravenous administration.
  • Example 1 A study similar to that described in In vivo Example 1 was performed using intravenous administration of compound 2 A.
  • a group of mice was treated with the compound, as the hydrochloride salt dissolved in aqueous 5% dextrose, at 40 and 80 mg/Kg by tail vein injection once/day for 5 consecutive days, with vehicle control.
  • Compound 2 A was active in this assay, causing 53% (40 mg/Kg) and 99% (80 mg/Kg) inhibition of tumor growth compared to vehicle.
  • Example 4 MiaPaCa-2 xenograft assay, intraperitoneal administration.
  • mice Male athymic nu/nu mice, 6-8 weeks old (approximately 20 g), were implanted subcutaneously in the right fore flank with 20-30 mg pieces of MIA PaCa-2 tumor harvested from similar nu/nu mice that had previously been implanted with the MIA PaCa-2 tumor. Approximately 7-10 days after tumor transplantation, when the tumor weight was approximately 50-200 mg, the mice were assigned to treatment groups such that each treatment group had a similar average tumor weight at the start of treatment.
  • mice A group of mice was treated with compounds 2 A, 3 A, and 5A, in all cases as the hydrochloride salts dissolved in aqueous 5% dextrose, at 100 mg/Kg by intraperitoneal injection once/day for 7 consecutive days, with vehicle control. All compounds were active in this assay, with tumor growth inhibition compared to vehicle of 89%, 89%, and 62% for compounds 2A, 3A, and 5A, respectively; though all animals showed some body weight loss.
  • Formulation Example 1 Pharmaceutical composition for oral administration.
  • a solid pharmaceutical composition for oral administration is prepared by combining the following: Compound of this invention 25.0% w/w
  • Hydroxypropylmethylcellulose 1.0% w/w Microcrystalline cellulose 71.5% w/w and the mixture is compressed to form tablets or filled into hard gelatin capsules containing, for example, 100 mg of the compound of this invention. Tablets may be coated, if desired, by applying a suspension of a film-forming agent (for example, hydroxypropylmethylcellulose), pigment (for example, titanium dioxide), and plasticizer (for example, diethyl phthalate), and drying the film by evaporation of the solvent.
  • a film-forming agent for example, hydroxypropylmethylcellulose
  • pigment for example, titanium dioxide
  • plasticizer for example, diethyl phthalate
  • a pharmaceutical composition for IV administration is prepared by dissolving a compound of this invention, for example as a pharmaceutically acceptable salt, to a concentration of 1% w/v in phosphate-buffered saline; and the solution is sterilized, for example by sterile filtration, and sealed in sterile containers containing, for example, 100 mg of a compound of this invention.
  • a lyophilized composition is prepared by dissolving a compound of this invention, again for example as a pharmaceutically acceptable salt, in a suitable buffer, for example the phosphate buffer of the phosphate-buffered saline mentioned above, sterilizing the solution and dispensing it into suitable sterile vials, lyophilizing the solution to remove the water, and sealing the vials.
  • the lyophilized composition is reconstituted by the addition of sterile water, and the reconstituted solution may be further diluted for administration with a solution such as 0.9% sodium chloride intravenous infusion or 5% dextrose intravenous infusion.
  • a compound of this invention diluted in 5% dextrose intravenous infusion, is administered intravenously over 30 minutes to a patient suffering from metastatic ovarian carcinoma at an initial dose of 100 mg/m 2 ; and this dose is increased to 250 mg/m 2 , 500 mg/m 2 , 750 mg/m 2 , and 1000 mg/m 2 .
  • the compound is administered at 1-week intervals.
  • the same dose escalation is administered at 2- and 3-week intervals to other patients suffering from the same cancer.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP06844637A 2006-11-29 2006-11-29 2-{[2-(substituierte amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidate Withdrawn EP2097139A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/045717 WO2008066526A1 (en) 2006-11-29 2006-11-29 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidates

Publications (1)

Publication Number Publication Date
EP2097139A1 true EP2097139A1 (de) 2009-09-09

Family

ID=38197807

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06844637A Withdrawn EP2097139A1 (de) 2006-11-29 2006-11-29 2-{[2-(substituierte amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidate

Country Status (7)

Country Link
EP (1) EP2097139A1 (de)
JP (1) JP2010511040A (de)
CN (1) CN101553282A (de)
AU (1) AU2006351255A1 (de)
CA (1) CA2670628A1 (de)
MX (1) MX2009005750A (de)
WO (1) WO2008066526A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015072275A1 (ja) 2013-11-12 2015-05-21 イーグル工業株式会社 分割型メカニカルシール

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600091A (en) * 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008066526A1 *

Also Published As

Publication number Publication date
CN101553282A (zh) 2009-10-07
WO2008066526A1 (en) 2008-06-05
JP2010511040A (ja) 2010-04-08
AU2006351255A1 (en) 2008-06-05
CA2670628A1 (en) 2008-06-05
MX2009005750A (es) 2009-07-14

Similar Documents

Publication Publication Date Title
US8093231B2 (en) Sulfonylethyl phosphorodiamidates
SK287123B6 (sk) Deriváty sulfónamidov a farmaceutický prostriedok, ktorý ich obsahuje
UA77296C2 (en) Phosphate prodrugs of fluoro-oxindols
DE69026964T2 (de) Gem-diphosphonsäuren, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US7655799B2 (en) 2{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates
US8334266B2 (en) Process for and intermediates in the preparation of canfosfamide and its salts
US20080125397A1 (en) 2 (SULFONYL)ETHYL N,N,N',N' tetrakis(2 chloroethyl)phosphorodia
WO2008066526A1 (en) 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidates
WO2008066515A1 (en) 2-({2-oxo-2-[(pyridin-3-ylmethyl)amino]ethyl}sulfonyl)ethyl n,n,n',n'-tetrakis(2-chloroethyl)phosphorodiamidate
KR20090087033A (ko) 2-｛［2-（치환 아미노）에틸］술포닐｝에틸 ｎ, ｎ, ｎ′,ｎ′-테트라키스（2-클로로에틸）포스포로디아미데이트
ZA200609498B (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
US7872134B2 (en) 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidates
UA74574C2 (en) Bis (n,n'-bis(2-halogenethyl)amino)phosphodiamates, a method for producing thereof (variants), a pharmaceutical composition containing them, and a method for the treatment of tumors
US20240101584A1 (en) Targeted delivery of 1,2,4,5 tetraoxane compounds and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20111118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120329